Key Financial Data Of Group

Kringle Pharma,Inc. - Filing #7338974

Concept 2023-10-01 to
2024-03-31
As at
2024-03-31
2024-01-01 to
2024-03-31
2022-10-01 to
2023-09-30
As at
2023-09-30
As at
2023-03-31
2023-01-01 to
2023-03-31
2022-10-01 to
2023-03-31
Key financial data of group
Business results of group
Net sales
43,029,000 JPY
69,250,000 JPY
34,353,000 JPY
Ordinary profit (loss)
-365,471,000 JPY
-852,660,000 JPY
-314,811,000 JPY
Net assets
2,322,294,000 JPY
2,021,702,000 JPY
2,480,078,000 JPY
Total assets
2,912,050,000 JPY
2,618,657,000 JPY
2,871,157,000 JPY
Basic earnings (loss) per share
-60.21
-30.60
-158.46
-29.29
-58.63
Diluted earnings per share
Equity-to-asset ratio
0.793 xbrli:pure
0.766 xbrli:pure
0.861 xbrli:pure
Net cash provided by (used in) operating activities
-315,253,000 JPY
-689,095,000 JPY
-294,458,000 JPY
Net cash provided by (used in) investing activities
-121,363,000 JPY
-120,875,000 JPY
-120,875,000 JPY
Net cash provided by (used in) financing activities
668,409,000 JPY
69,164,000 JPY
2,600,000 JPY
Cash and cash equivalents
1,993,032,000 JPY
1,761,239,000 JPY
2,089,311,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.